Palobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of 2018. The studies will evaluate the preliminary efficacy of PBF-677 in Ulcerative Colitis patients and the efficacy of PBF-680 is mild to moderate asthmatics.
News
Palobiofarma advances it´s broad clinical pipeline
2
Related News
2
FDA grants Palobiofarma approval to start second anti-cancer study in USA
Palobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of...
No Comments
2
Palobiofarma initiates clinical development of it´s novel dual PDE10/A2a antagonist in solid tumors
Palobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of...
No Comments
2
Palobiofarma achieves “first patient first visit” in two key Phase II studies
Palobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of...
No Comments
2
Palobiofarma completed the dose escalation part of the Phase I study with PBF-999 in cancer patients
Palobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of...
3 Comments